2021
Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
Ward Z, Stone J, Bishop C, Ivakin V, Eritsyan K, Deryabina A, Low A, Cepeda J, Kelly SL, Heimer R, Cook R, Altice FL, Litz T, Terlikbayeva A, El-Bassel N, Havarkov D, Fisenka A, Boshnakova A, Klepikov A, Saliuk T, Deshko T, Vickerman P. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis. The Lancet HIV 2021, 9: e42-e53. PMID: 34895484, PMCID: PMC8762142, DOI: 10.1016/s2352-3018(21)00274-5.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAgonist therapyAntiretroviral therapyPublic health approachHIV transmissionDrug useDynamic HIV transmission modelHealth approachIncremental cost-effectiveness ratioHIV transmission modelNational InstituteCost-effectiveness ratioCountry-specific costsHIV incidenceUNAIDS 90US National InstitutesART coverageWHO targetPWIDTherapyPay thresholdsInfectious diseasesCost savingsDrug abuseIncremental cost
2016
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States
Sweet DE, Altice FL, Cohen CJ, Vandewalle B. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLOS ONE 2016, 11: e0147821. PMID: 26808503, PMCID: PMC4725959, DOI: 10.1371/journal.pone.0147821.Peer-Reviewed Original ResearchConceptsSingle-tablet regimensSubstantial price reductionsTenofovir disoproxil fumarate/emtricitabineCost-effectiveness thresholdIncremental cost-effectiveness ratioGeneric medicationsDaily single-tablet regimensDisoproxil fumarate/emtricitabineCost-effectiveness ratioElvitegravir/cobicistatCombination antiretroviral therapyHIV-1 patientsSingle-tablet regimenHigher inpatient costsHIV-1 infectionIncremental lifetime costPrice reductionEconomic outcomesMicrosimulation modelSuch policiesGeneric lamivudineTablet regimensAntiretroviral therapyU.S. settingsComplex regimens